The analysis indicates that using Hemospray (TC-325) as a first-line treatment for malignant upper gastrointestinal bleeding is both more effective and cost-saving than standard endoscopic therapy (SET). It demonstrated a cost reduction of £245.88, with a slight increase in quality-adjusted life years (0.001 QALYs). In probabilistic simulations, TC-325 proved more effective and economically favorable in 82% of cases. Overall, it resulted in fewer interventions and reduced hospital stays, warranting further research.
Journal Article by Cooper DA, Norton B (…) Barkun A et 5 al. in Endoscopy
The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).